Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Alto Neuroscience, Inc.NYSE: ANRO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $26.24M (cash outflow) rose 73.0% year over year, ahead of the +17.6% change in trailing-twelve-month net income. Sequentially, it rose 62.1% from the prior quarter. Over 3 fiscal years it compounded at +31.7% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$104.03M (+64.5%) for the fiscal year ending Dec 2026, a step up from the +2.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.24M+62.1% QoQ
- Last fiscal yearDec 2025
- -$63.24M+2.9% YoY
- LTMMar 2026
- -$74.31M+17.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +73.0% | +33.4% | -39.5 pp |
| 1 year | +2.9% | +64.5% | +61.6 pp |
| 3-year CAGR | +31.7% | +16.4% | -15.2 pp |
| 5-year CAGR | -13.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (63.24M) USD
- Year-over-year change
- -2.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (63.24M) | -2.9% |
| FY2024 | 2024-12-31 | (61.43M) | -69.2% |
| FY2023 | 2023-12-31 | (36.31M) | -31.0% |
| FY2022 | 2022-12-31 | (27.71M) | -201.6% |
| FY2021 | 2021-12-31 | (9.19M) | — |
Net Income vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.6% is the 7th highest of 10, against a peer median of +34.3%.
- Over three fiscal years its annual growth of +31.7% compares with a peer median of +11.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $167.47M USD | +47.3% | +15.1% | — | |
| LTM Mar 2026 | $166.01M USD | +74.3% | +67.3% | — | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $113.5M USD | +29.8% | +26.4% | 2954.1% | |
| LTM Mar 2026 | $74.31M USD | +17.6% | +31.7% | — | |
| LTM Dec 2025 | CHF 70.34M CHF | +38.1% | -1.7% | 1968.6% | |
| LTM Mar 2026 | $67.27M USD | +11.1% | -11.8% | 98.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M USD | +17.3% | +35.2% | — |
| LTM Dec 2025 | $42.63M USD | +34.3% | +8.1% | — | |
| LTM Mar 2026 | $27.37M USD | -52.6% | -18.3% | — | |
| LTM Mar 2026 | $5.23M USD | +106.0% | -28.4% | 2.4% | |
| Peer median (excluding ANRO) | — | +34.3% | +11.6% | 1968.6% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M | 8.11M |
| Change in Working Capital | (572K) | 4.58M | (698K) | 4.06M | 33K |
| Accounts Receivables | (1.29M) | 1.16M | 325K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 458K | 1.01M | (632K) | 516K | 221K |
| Other Working Capital | 255K | 2.42M | (391K) | 3.54M | (188K) |
| Other Non-Cash Items | 125K | 632K | 291K | 1.81M | 2.67M |
| Operating Cash Flow | (9.26M) | (20.39M) | (33.45M) | (47.42M) | (51.77M) |
| Capital Expenditures | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Debt Repayment | 0 | 9.83M | 0 | 1.25M | 9.48M |
| Common Stock Issued | 7K | 43K | 181K | 137.58M | 50.7M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (167K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (205K) | (341K) | (2.05M) | (3.14M) | 67K |
| Financing Cash Flow | 31.69M | 43.79M | 68.13M | 135.69M | 60.08M |
| Effect of Forex Changes | (50K) | (24K) | (8K) | (11K) | (30K) |
| Net Change in Cash | 21.7M | 22.64M | 34.2M | 86.18M | 8.26M |
| Free Cash Flow | (9.94M) | (21.13M) | (33.92M) | (49.5M) | (51.79M) |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.